Andy Geall
About Andy Geall
Andy Geall is the Co-founder and Chief Development Officer at Replicate Bioscience, Inc., with extensive experience in mRNA vaccines and nucleic acid delivery. He has a strong academic background and has held significant roles in various biotechnology companies, demonstrating expertise in transitioning research to clinical applications and securing funding.
Work at Replicate Bioscience, Inc.
Andy Geall serves as the Co-founder and Chief Development Officer at Replicate Bioscience, Inc. since 2021. In this role, he focuses on advancing the company's mission in the biotechnology sector, particularly in the development of innovative therapies. His leadership is pivotal in guiding the strategic direction of the company, leveraging his extensive experience in the field.
Education and Expertise
Andy Geall has a robust educational background in pharmacy and chemical engineering. He earned a Bachelor's Degree in Pharmacy from the University of Bath, followed by a Doctor of Philosophy (Ph.D.) in Gene Delivery Systems from the same institution. Additionally, he studied Chemical Engineering at the University of Edinburgh. His postdoctoral research includes work at the St Helens and Knowsley Trust Hospitals and The Picower Institute for Medical Research, focusing on gene delivery and malaria.
Background in Pharmaceutical Development
Geall has a strong background in transitioning innovative research into clinical testing. His experience spans various roles in the pharmaceutical industry, including Vice President of Formulations and Chemistry at Avidity Biosciences LLC and Chief Scientific Officer at Precision NanoSystems Inc. His expertise encompasses technology scale-up and GMP production, indicating a comprehensive understanding of the development process from research to market.
Achievements in mRNA Vaccines and Fundraising
Andy Geall has pioneered advancements in mRNA vaccines and nucleic acid delivery, contributing significantly to the field. He has demonstrated proficiency in fundraising from government agencies and venture capital, showcasing a strategic approach to securing resources necessary for research and development initiatives.